TITLE:
Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

CONDITION:
Kidney Disease

INTERVENTION:
Placebo

SUMMARY:

      The purpose of this study is to assess the impact of treatment of anemia with darbepoetin
      alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal
      cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects
      with chronic kidney disease and type 2 diabetes mellitus.

      Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Hemoglobin less than or equal to 11 g/dL

          -  History of Chronic Kidney Disease

          -  eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73
             m2 and less than or equal to 60 mL/min/1.73 m2

          -  Tsat (transferrin saturation) greater than 15%

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Erythropoietic protein use within 12 weeks of randomization
      
